Viridian Therapeutics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
252
- Stock Symbol
-
VRDN
- Investments
-
2
- Share Price
-
$31.44
- (As of Thursday Closing)
Viridian Therapeutics General Information
Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Contact Information
Website
www.viridiantherapeutics.comCorporate Office
- 221 Crescent Street
- Suite 103A
- Waltham, MA 02453
- United States
Corporate Office
- 221 Crescent Street
- Suite 103A
- Waltham, MA 02453
- United States
Viridian Therapeutics Stock Performance
As of 19-Nov-2026, Viridian Therapeutics’s stock price is $31.44. Its current market cap is $3.57B with 114M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $31.44 | $30.12 | $13.18 - $34.29 | $3.57B | 114M | 2.13M | -$3.83 |
Viridian Therapeutics Financials Summary
As of 30-Sep-2026, Viridian Therapeutics has a trailing 12-month revenue of $26.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,692,063 | 2,689,759 | 975,265 | 988,050 |
| Revenue | 26,309 | 70,849 | 302 | 314 |
| EBITDA | (462,250) | (364,592) | (298,809) | (254,121) |
| Net Income | (453,584) | (342,601) | (269,949) | (237,734) |
| Total Assets | 1,028,670 | 899,418 | 742,403 | 490,424 |
| Total Debt | 243,267 | 50,693 | 21,095 | 21,048 |
Viridian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Viridian Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Viridian Therapeutics Comparisons
Industry
Financing
Details
Viridian Therapeutics Competitors (14)
One of Viridian Therapeutics’s 14 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sling Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Harbour BioMed | Formerly VC-backed | Shanghai, China | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI |
Viridian Therapeutics Patents
Viridian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128897-A1 | Methods for treatment of chronic thyroid eye disease | Pending | 15-Dec-2024 | ||
| WO-2026128897-A8 | Methods for treatment of chronic thyroid eye disease | Pending | 15-Dec-2024 | ||
| WO-2026102438-A1 | Method for delivering fc fusion molecule | Pending | 11-Nov-2024 | ||
| WO-2026055673-A1 | Methods for treatment of thyroid eye disease with an anti-igf-1r antibody | Pending | 09-Sep-2024 | ||
| WO-2025151492-A1 | Compositions and methods for treatment of thyroid eye disease | Inactive | 09-Jan-2024 | C07K16/2863 |
Viridian Therapeutics Signals
Viridian Therapeutics Acquisitions (2)
Viridian Therapeutics’s most recent deal was a Merger/Acquisition with Viridian Therapeutics (Biotechnology) for . The deal was made on 27-Oct-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Viridian Therapeutics (Biotechnology) | 27-Oct-2020 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Signal Genetics | 13-Feb-2017 | Merger/Acquisition | Biotechnology |
Viridian Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Viridian Therapeutics FAQs
-
When was Viridian Therapeutics founded?
Viridian Therapeutics was founded in 2007.
-
Where is Viridian Therapeutics headquartered?
Viridian Therapeutics is headquartered in Waltham, MA.
-
What is the size of Viridian Therapeutics?
Viridian Therapeutics has 252 total employees.
-
What industry is Viridian Therapeutics in?
Viridian Therapeutics’s primary industry is Drug Discovery.
-
Is Viridian Therapeutics a private or public company?
Viridian Therapeutics is a Public company.
-
What is Viridian Therapeutics’s stock symbol?
The ticker symbol for Viridian Therapeutics is VRDN.
-
What is the current stock price of Viridian Therapeutics?
As of 19-Nov-2026 the stock price of Viridian Therapeutics is $31.44.
-
What is the current market cap of Viridian Therapeutics?
The current market capitalization of Viridian Therapeutics is $3.57B.
-
What is Viridian Therapeutics’s current revenue?
The trailing twelve month revenue for Viridian Therapeutics is $26.3M.
-
Who are Viridian Therapeutics’s competitors?
Sarepta Therapeutics, Sling Therapeutics, Intellia Therapeutics, Harbour BioMed, and ONL Therapeutics are some of the 14 competitors of Viridian Therapeutics.
-
What is Viridian Therapeutics’s annual earnings per share (EPS)?
Viridian Therapeutics’s EPS for 12 months was -$3.83.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process